Authors

  • Dilnoza Jalilova
    Tashkent Pediatric Medical Institute Clinical Residency
  • S. Yuldasheva
    Tashkent Pediatric Medical Institute Clinical Residency

DOI:

https://doi.org/10.71337/inlibrary.uz.ijai.125745

Abstract

An increase in the level of follicle-stimulating hormone (FSH) in women of reproductive age is one of the key markers of decreased ovarian reserve and a harbinger of reproductive failure. The article discusses the pathophysiological mechanisms of increased FSH, its diagnostic value and clinical significance in the context of infertility. The article presents the results of the analysis of data from 152 patients with varying degrees of increased FSH, and studies possible causes (age-related changes, iatrogenic interventions, autoimmune processes, genetic predisposition) and potential approaches to treatment. Modern strategies for patient management are covered, including the use of hormone replacement therapy, an individualized ovarian stimulation protocol, the use of donor oocytes, as well as innovative methods using growth factors and stem cells. Emphasis is placed on the need for a differentiated approach and careful assessment of the ovarian reserve in clinical practice.

 

 

background image

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23

American Academic publishers, volume 05, issue 07,2025

Journal:

https://www.academicpublishers.org/journals/index.php/ijai

page 170

HIGH FSH AND THE EFFECTIVENESS OF ART PROGRAMS: MODERN

APPROACHES TO PATIENT MANAGEMENT

Jalilova Dilnoza Juraevna

Tashkent Pediatric Medical Institute

Clinical Residency

Scientific Supervisor:

S.Z. Yuldasheva

Annotation:

An increase in the level of follicle-stimulating hormone (FSH) in women of

reproductive age is one of the key markers of decreased ovarian reserve and a harbinger of

reproductive failure. The article discusses the pathophysiological mechanisms of increased FSH,

its diagnostic value and clinical significance in the context of infertility. The article presents the

results of the analysis of data from 152 patients with varying degrees of increased FSH, and

studies possible causes (age-related changes, iatrogenic interventions, autoimmune processes,

genetic predisposition) and potential approaches to treatment. Modern strategies for patient

management are covered, including the use of hormone replacement therapy, an individualized

ovarian stimulation protocol, the use of donor oocytes, as well as innovative methods using

growth factors and stem cells. Emphasis is placed on the need for a differentiated approach and

careful assessment of the ovarian reserve in clinical practice.

Keywords:

Follicle stimulating hormone, FSH, infertility, ovarian reserve, AMH, hormonal

therapy, donor eggs, IVF, premature ovarian failure, decreased fertility

Introduction

A woman's reproductive function directly depends on the state of the ovarian reserve, the

key biomarker of which is the level of follicle-stimulating hormone (FSH). Elevated FSH,

especially in the early follicular phase of the menstrual cycle, is a prognostic sign of decreased

ovarian function. The FSH level closely correlates with the number of antral follicles and anti-

Müllerian hormone (AMH), which makes it one of the most studied and clinically significant

parameters in the diagnosis of infertility. An increase in FSH is usually associated with a

compensatory increase in pituitary stimulation during depletion of the follicular pool. However,

interpretation of the FSH level requires a comprehensive approach that takes into account the

patient's age, cycle phase, the presence of concomitant pathology and previously performed

treatment methods.

Methods

The study included 152 patients diagnosed with infertility of various origins and confirmed

elevated FSH levels (>10 MME/ml). The women's age ranged from 28 to 43 years. The patients

were divided into 3 groups: Group I — with moderate FSH elevation (10–15 MME/ml), Group


background image

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23

American Academic publishers, volume 05, issue 07,2025

Journal:

https://www.academicpublishers.org/journals/index.php/ijai

page 171

II — with marked elevation (15–25 MME/ml), Group III — with critical levels (>25 MME/ml).

All women underwent a comprehensive examination: determination of FSH, LH, E2, AMH,

ultrasound monitoring of the ovaries, karyotyping, study of autoantibodies to ovarian tissue,

and assessment of somatic status. In some cases, enzyme immunoassay methods were used to

exclude concomitant endocrine disorders. The effectiveness of various treatment approaches

was assessed, including hormonal therapy, IVF with the woman's own or donor oocytes,

ovulation induction, and experimental methods.

Results

Analysis of clinical data revealed a direct relationship between the FSH level and the

severity of menstrual cycle disorders. Patients with FSH> 25 MME/ml more often had

amenorrhea or infrequent menstruation, as well as low E2 and AMH levels, indicating profound

ovarian dysfunction. Autoantibodies to ovarian tissues were detected in 78% of women in

Group III, confirming the involvement of the autoimmune mechanism in pathogenesis.

Mutations in the FMR1 gene (premutation) were diagnosed in 16% of patients, which correlates

with the clinical picture of premature ovarian failure. The effectiveness of classical IVF

protocols with their own eggs in this category of patients was extremely low (the overall

pregnancy rate was 5.6%). The highest result (up to 47%) was shown by the protocol using

donor oocytes. The use of hormone replacement therapy allowed to normalize the menstrual

cycle and subjective well-being in most patients, but did not affect the restoration of fertility.

Injections of stem cells and growth factors in the experimental group demonstrated positive

dynamics of the AMH level in 3 of 12 patients during 6 months of observation, but require

further research.

Discussion

An elevated FSH level in women with infertility is an important marker indicating a

decrease in ovarian reserve and the need to revise reproductive tactics. Its interpretation should

be comprehensive and take into account age, hormonal background, the presence of

concomitant pathology and previous reproductive failures. This indicator should not be the only

criterion for refusing IVF attempts, especially with a moderate increase (up to 15-18 MME/ml),

where individualized stimulation is possible. However, with a pronounced and critical FSH

level (>25 MME/ml), it is rational to use programs with donor eggs or participate in clinical

trials of new methods for restoring ovarian function. The autoimmune component and genetic

predisposition emphasize the need for extensive screening and a multidisciplinary approach to

diagnosis and treatment.

Conclusion

Elevated FSH levels are a prognostically unfavorable factor in women with infertility,

especially in combination with low AMH and menstrual irregularities. Individualization of the

approach, timely diagnosis of causes, expansion of indications for the use of assisted

reproductive technologies and the development of new experimental methods are key areas in

the management of such patients. Further research in the field of molecular biology,


background image

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23

American Academic publishers, volume 05, issue 07,2025

Journal:

https://www.academicpublishers.org/journals/index.php/ijai

page 172

immunology and regenerative medicine will help expand therapeutic options and improve the

fertility prognosis.

Sources Used:

1. Savelyeva G.M., Serov V.N. "Gynecology". – M.: GEOTAR-Media, 2020.

2. Practice Committee of the American Society for Reproductive Medicine. "Testing and

interpreting measures of ovarian reserve: a committee opinion." Fertility and Sterility. 2020.

3. Livshits V.A., Andreeva E.N. "Reproductive endocrinology". – M.: MIA, 2019.

4. Nelson LM "Primary ovarian insufficiency." New England Journal of Medicine, 2009.

5. Tartagni M., et al. "Premature ovarian failure: genetic and autoimmune causes." European

Review for Medical and Pharmacological Sciences, 2015.

6. Kelsey TW, et al. "Ovarian volume correlates strongly with ovarian reserve markers."

Human Reproduction, 2013.

7. Yaroshevich A.M., Shmyrov A.D. "Modern approaches to the management of patients with

premature ovarian failure". Obstetrics and Gynecology, 2021.

8. Dolzhenko M.M. "Assisted Reproductive Technologies: Present and Future". Reproductive

Health, 2020.

9. Check JH "High FSH levels: the clinical significance and approach to management."

Clinical and Experimental Obstetrics & Gynecology, 2018.

10. Oktay K., et al. "In vitro activation of primordial follicles using Akt stimulators and stem

cells: a new horizon for fertility preservation." Fertility and Sterility, 2022.

References

Savelyeva G.M., Serov V.N. "Gynecology". – M.: GEOTAR-Media, 2020.

Practice Committee of the American Society for Reproductive Medicine. "Testing and interpreting measures of ovarian reserve: a committee opinion." Fertility and Sterility. 2020.

Livshits V.A., Andreeva E.N. "Reproductive endocrinology". – M.: MIA, 2019.

Nelson LM "Primary ovarian insufficiency." New England Journal of Medicine, 2009.

Tartagni M., et al. "Premature ovarian failure: genetic and autoimmune causes." European Review for Medical and Pharmacological Sciences, 2015.

Kelsey TW, et al. "Ovarian volume correlates strongly with ovarian reserve markers." Human Reproduction, 2013.

Yaroshevich A.M., Shmyrov A.D. "Modern approaches to the management of patients with premature ovarian failure". Obstetrics and Gynecology, 2021.

Dolzhenko M.M. "Assisted Reproductive Technologies: Present and Future". Reproductive Health, 2020.

Check JH "High FSH levels: the clinical significance and approach to management." Clinical and Experimental Obstetrics & Gynecology, 2018.

Oktay K., et al. "In vitro activation of primordial follicles using Akt stimulators and stem cells: a new horizon for fertility preservation." Fertility and Sterility, 2022.